ABBV-467

News alerts, weekly reports and conference planners

Company:

AbbVie

Drug class:

MCL1 inhibitor

Related drugs:

1year

Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients. (PubMed, Commun Med (Lond))

The selectivity of ABBV-467 suggests that treatment-induced troponin release is a consequence of MCL-1 inhibition and therefore may represent a class effect of MCL-1 inhibitors in human patients.

1 year ago

Preclinical • Journal

BCL2 (B-cell CLL/lymphoma 2)

Venclexta (venetoclax) • ABBV-467

2years

NA1-115-7, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes. (PubMed, Biomed Pharmacother)

Synthetic inhibitors targeting these proteins have been developed, and some hematological malignancies are now widely treated with a BCL-2 inhibitor (venetoclax)...Six MCL-1 inhibitors (S64315, AZD-5991, AMG-176, AMG-397, ABBV-467 and PRT1419) have been evaluated in clinical trials since 2016, but some were affected by safety issues and none are currently used clinically...Importantly, a similar treatment with NA1-115-7 was not toxic to erythrocytes, peripheral blood mononuclear cells, platelets, or cardiomyocytes. These results highlight the potential of natural products for use as specific BH3 mimetics non-toxic to normal cells, and they suggest that NA1-115-7 may be a promising tool for use in cancer treatment.

2 years ago

Journal • IO biomarker

BCL2L1 (BCL2-like 1)

MCL1 expression

Venclexta (venetoclax) • AZD5991 • tapotoclax (AMG 176) • PRT1419 • ABBV-467 • MIK665 • murizatoclax (AMG 397)